FIGURE 4.
Effect on survival from the day of initiating gefitinib treatment in recurrent non small-cell lung cancer (NSCLC) after surgery by epidermal growth factor receptor (EGFR) activating mutation (A) and KRAS mutation (B) status.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.